These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 28124822)

  • 1. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Samkani A; Pedersen LR; Boston RC; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2019 Aug; 21(8):2012-2016. PubMed ID: 31050161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.
    Anholm C; Kumarathurai P; Klit MS; Kristiansen OP; Nielsen OW; Ladelund S; Madsbad S; Sajadieh A; Haugaard SB;
    BMJ Open; 2014 Jul; 4(7):e005942. PubMed ID: 25031198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
    Tanaka K; Saisho Y; Manesso E; Tanaka M; Meguro S; Irie J; Sugiura H; Kawai T; Jinzaki M; Cobelli C; Itoh H;
    Clin Drug Investig; 2015 Oct; 35(10):675-84. PubMed ID: 26369653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
    Kumarathurai P; Anholm C; Larsen BS; Olsen RH; Madsbad S; Kristiansen O; Nielsen OW; Haugaard SB; Sajadieh A
    Diabetes Care; 2017 Jan; 40(1):117-124. PubMed ID: 27797930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
    Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
    Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
    Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
    Chen XM; Zhang WQ; Tian Y; Wang LF; Chen CC; Qiu CM
    Cardiovasc Diabetol; 2018 Apr; 17(1):53. PubMed ID: 29636047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-Year Treatment With Metformin During Puberty Does Not Preserve β-Cell Function in Youth With Obesity.
    Kelsey MM; Hilkin A; Pyle L; Severn C; Utzschneider K; Van Pelt RE; Zeitler PS; Nadeau KJ
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2622-e2632. PubMed ID: 33728428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes.
    Bi Y; Tong GY; Yang HJ; Cai MY; Ma JH; Liang J; Xin B; Miao H; Peng ZH; Zhu DL
    Diabetes Metab Res Rev; 2013 Nov; 29(8):664-72. PubMed ID: 23955995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B
    Digenio A; Pham NC; Watts LM; Morgan ES; Jung SW; Baker BF; Geary RS; Bhanot S
    Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
    RISE Consortium
    Diabetes Care; 2019 Sep; 42(9):1742-1751. PubMed ID: 31178434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
    RISE Consortium
    Diabetes Care; 2014; 37(3):780-8. PubMed ID: 24194506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus].
    Chen P; Huang Q; Xu XJ; Shao ZL; Huang LH; Yang XZ; Guo W; Li CM; Chen C
    Zhonghua Nei Ke Za Zhi; 2016 May; 55(5):349-54. PubMed ID: 27143183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.
    Liu Y; Jiang X; Chen X
    Lipids Health Dis; 2017 Dec; 16(1):227. PubMed ID: 29197387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.
    Hage C; Brismar K; Efendic S; Lundman P; Rydén L; Mellbin L
    J Intern Med; 2013 Apr; 273(4):410-21. PubMed ID: 23331339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.